1. Home
  2. HOWL vs VIGL Comparison

HOWL vs VIGL Comparison

Compare HOWL & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HOWL
  • VIGL
  • Stock Information
  • Founded
  • HOWL 2017
  • VIGL 2020
  • Country
  • HOWL United States
  • VIGL United States
  • Employees
  • HOWL N/A
  • VIGL N/A
  • Industry
  • HOWL Biotechnology: Pharmaceutical Preparations
  • VIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • HOWL Health Care
  • VIGL Health Care
  • Exchange
  • HOWL Nasdaq
  • VIGL Nasdaq
  • Market Cap
  • HOWL 87.4M
  • VIGL 89.3M
  • IPO Year
  • HOWL 2021
  • VIGL 2022
  • Fundamental
  • Price
  • HOWL $1.36
  • VIGL $2.64
  • Analyst Decision
  • HOWL Strong Buy
  • VIGL Strong Buy
  • Analyst Count
  • HOWL 2
  • VIGL 5
  • Target Price
  • HOWL $9.50
  • VIGL $21.00
  • AVG Volume (30 Days)
  • HOWL 263.3K
  • VIGL 2.6M
  • Earning Date
  • HOWL 03-06-2025
  • VIGL 03-25-2025
  • Dividend Yield
  • HOWL N/A
  • VIGL N/A
  • EPS Growth
  • HOWL N/A
  • VIGL N/A
  • EPS
  • HOWL N/A
  • VIGL N/A
  • Revenue
  • HOWL $3,386,000.00
  • VIGL N/A
  • Revenue This Year
  • HOWL N/A
  • VIGL N/A
  • Revenue Next Year
  • HOWL $34.17
  • VIGL N/A
  • P/E Ratio
  • HOWL N/A
  • VIGL N/A
  • Revenue Growth
  • HOWL N/A
  • VIGL N/A
  • 52 Week Low
  • HOWL $1.26
  • VIGL $1.49
  • 52 Week High
  • HOWL $8.19
  • VIGL $6.06
  • Technical
  • Relative Strength Index (RSI)
  • HOWL 41.40
  • VIGL 71.47
  • Support Level
  • HOWL $1.26
  • VIGL $2.22
  • Resistance Level
  • HOWL $1.45
  • VIGL $2.53
  • Average True Range (ATR)
  • HOWL 0.09
  • VIGL 0.29
  • MACD
  • HOWL 0.02
  • VIGL 0.08
  • Stochastic Oscillator
  • HOWL 45.45
  • VIGL 80.47

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Share on Social Networks: